Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 7/20 | 0.47 |
| ▸ | CDK9 | P50750 | 7/20 | 0.47 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 7/20 | 0.43 |
| ▸ | DRD2 | P14416 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436505 | 0.88 | CCNT1 (0.47) | CCNT1CDK9SUV39H2HTR1ADRD2 | |
| SCHEMBL3434596 | 0.82 | CCNT1 (0.52) | CCNT1CDK9DRD2HTR1DHTR1B | |
| SCHEMBL2078054 | 0.79 | KDM4E (0.43) | CCNT1CDK9SUV39H2HTR1AKDM4E | |
| SCHEMBL31247832 | 0.77 | PDK4 (0.53) | KDM4EMAPT | |
| SCHEMBL520056 | 0.77 | SUV39H2 (0.53) | CCNT1CDK9SUV39H2KDM4EALDH1A1 | |
| SCHEMBL521942 | 0.75 | CCNT1 (0.50) | CCNT1CDK9SUV39H2ALDH1A1MAPT | |
| SCHEMBL3434233 | 0.75 | CDK9 (0.52) | CCNT1CDK9HTR1DHTR1B | |
| SCHEMBL3436230 | 0.74 | CCNT1 (0.47) | CCNT1CDK9SUV39H2KDM4EMAPT | |
| SCHEMBL3436504 | 0.74 | CDK9 (0.53) | CCNT1CDK9DRD2 | |
| SCHEMBL3436391 | 0.73 | KDM4E (0.45) | CCNT1CDK9SUV39H2HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | CCNT1 3047/4885CDK9 648/4885SUV39H2 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.